West Pharmaceutical Services, Inc.

As of June 30, 2026, West Pharmaceutical Services, Inc. carries a market capitalization of 22.10B, placing it among publicly traded companies globally. Its enterprise value stands at 21.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

West Pharmaceutical Services, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, West Pharmaceutical Services, Inc. has 70.40M shares outstanding.

As of June 30, 2026, West Pharmaceutical Services, Inc. trades at a trailing price-to-earnings ratio of 45.60. The price-to-sales ratio is 7.74, and the price-to-book ratio stands at 8.44.

As of June 30, 2026, West Pharmaceutical Services, Inc. trades at an EV/EBITDA multiple of 29.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.92 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. West Pharmaceutical Services, Inc. trades at an EV/FCF ratio of 37.74, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 21.99B versus a market cap of 22.10B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, West Pharmaceutical Services, Inc. maintains a current ratio of 2.82, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.44, indicating elevated leverage, while an interest coverage ratio of 191.51 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, West Pharmaceutical Services, Inc. posted a return on equity (ROE) of 19.09, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.07, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.40, useful for judging operating efficiency across full business cycles. The company generates approximately 270,878.89 in revenue per employee across its workforce of 10,750.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.84 indicates how many times West Pharmaceutical Services, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, West Pharmaceutical Services, Inc. recorded 126.22M in income tax expense. That works out to an effective tax rate of 20.79, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 607.11M, leaving 494.46M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, West Pharmaceutical Services, Inc.'s stock has gained approximately 45.81% over the past 52 weeks. The 50-day moving average sits at 315.86, while the 200-day moving average is 269.05.

Over the twelve months ended June 30, 2026, West Pharmaceutical Services, Inc. generated 2.91B in revenue and converted that into 494.46M in net income, yielding earnings per share of 6.84. EBITDA reached 754.33M, while operating income came in at 632.49M.

As of June 30, 2026, West Pharmaceutical Services, Inc. holds 381.46M in cash and equivalents against 273.18M in total debt, resulting in a net debt position of -203.86M. Total book value stands at 2.62B, with working capital of 1.02B providing operational flexibility.

West Pharmaceutical Services, Inc. produced 579.62M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, West Pharmaceutical Services, Inc. posted a gross margin of 36.79, reflecting its pricing power and cost economics. The operating margin of 21.72 and net profit margin of 16.98 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, West Pharmaceutical Services, Inc. paid dividends of 0.76 per share. The dividend payout ratio of 11.05 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.56, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to West Pharmaceutical Services, Inc. shareholders.

West Pharmaceutical Services, Inc.'s most recent stock split took place on September 27, 2013 with a 1:2 split ratio.

As of June 30, 2026, West Pharmaceutical Services, Inc. has an Altman Z-Score of 17.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.